Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • COMMENT

Disproportional inflation of clinical trial costs: why we should care, and what we should do about it

Clinical trial costs seem to be inflating excessively, without a clear increase in the value of the information gained. Here, we highlight factors that could be driving this trend and discuss potential solutions.
  1. Hemme J. Hijma

    1. Centre for Human Drug Research, Leiden, The Netherlands.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  2. Ahnjili Zhuparris

    1. Centre for Human Drug Research, Leiden, The Netherlands.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  3. Ewoud-Jan van Hoogdalem

    1. ICON, Groningen, The Netherlands.

    View author publications

    You can also search for this author in PubMed  Google Scholar

  4. Adam F. Cohen

    1. Centre for Human Drug Research, Leiden, The Netherlands; Leiden University Medical Centre, Leiden, The Netherlands.

    View author publications

    You can also search for this author in PubMed  Google Scholar

Introduction

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 23, 85-86 (2024)

doi: https://doi.org/10.1038/d41573-024-00002-w

References

  1. Martin, L., Hutchens, M., Hawkins, C. & Radnov, A. How much do clinical trials cost? Nat. Rev. Drug Discov. 16, 381–382 (2017).

    Article  PubMed  Google Scholar 

  2. Yamaguchi, S., Kaneko, M. & Narukawa, M. Approval success rates of drug candidates based on target, action, modality, application, and their combinations. Clin. Transl Sci. 14, 1113–1122 (2021).

    Article  PubMed  Google Scholar 

  3. Beaver, J. A. & Pazdur, R. The wild west of checkpoint inhibitor development. N. Engl. J. Med. 386, 1297–1301 (2021).

    Article  PubMed  Google Scholar 

  4. DiMasi, J. A. et al. Assessing the financial value of decentralized clinical trials. Ther. Innov. Regul. Sci. 57, 209–219 (2022).

    Article  PubMed  Google Scholar 

  5. Cohen, A., Ultee, R. & van Veldhoven, G. Making pharmaceutical companies report what matters about innovation. Br. J. Clin. Pharmacol. 88, 2583–2587 (2022).

    Article  PubMed  Google Scholar 

  6. Wolinetz, C. D. & Tabak, L. A. Transforming clinical research to meet health challenges. JAMA 329, 1740 (2023).

    Article  PubMed  Google Scholar 

Download references

Supplementary Information

  1. Supplementary Figure 1

Competing Interests

The authors declare no competing interests. The manuscript represents views and opinions of the authors and do not necessarily represent opinion of the Centre for Human Drug Research or ICON.

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links